Key facts
- Notable investors include Changzhou Venture Capital Group, Pingling Capital, Jiangsu Sukong Venture Capital, Wuxi Xuantong Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Ogo Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Ogo Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ogo Biotech
Producer of bio-enzyme preparations for low-sugar and sugar-free foods and beverages. The company is committed to the research and development of bio-enzyme preparations and bio-enzyme (microorganism) fermentation technology, using bio-enzyme methods to produce functional sugars and functional sugar application products, permitting to produce feed-grade amino acids, pharmaceutical-grade amino acids, nucleotides and other products through synthetic biotechnology.
- Sector
- Healthcare
- HQ
- Changzhou, China
- Founded
- 2008
- Employees
- 500
- Website
- ogobiotech.com/
- Ownership
- Privately Held (backing)
Ogo Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ogo Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ogo Biotech in its N-PORT filings yet. We sweep new filings monthly.